Breaking News Instant updates and real-time market news.

PCAR

Paccar

$66.68

0.4 (0.60%)

, NAV

Navistar

$26.83

0.29 (1.09%)

14:07
10/03/19
10/03
14:07
10/03/19
14:07

Class 8 truck order Intake improved in September, ACT Research says

Preliminary North America Class 8 net order data show the industry booked 12,600 units in September, up 13% from August, while Classes 5-7 orders fell 9.4% m/m, to 17,300 units. Note that these numbers are preliminary. Complete industry data for September, including final order numbers, will be published by ACT Research in mid-October, says ACT Research."Little has changed since August with respect to the freight market and freight rates, while uncertainties surrounding trade and tariffs continue to weigh on truck buyers' psyches," said Steve Tam, ACT's Vice-President. He continued, "Fleet overcapacitization has led to reduced utilization, with all the foregoing considerations conspiring to undermine demand," added ACT Research. Companies in the truck manufacturing space include Paccar (PCAR),Navistar (NAV),Oshkosh (OSK),Cummins (CMI),Wabash(WNC) and Meritor (MTOR). Reference Link

PCAR

Paccar

$66.68

0.4 (0.60%)

NAV

Navistar

$26.83

0.29 (1.09%)

OSK

Oshkosh

$71.43

-1.76 (-2.40%)

CMI

Cummins

$154.02

-0.06 (-0.04%)

WNC

Wabash

$13.50

-0.05 (-0.37%)

MTOR

Meritor

$17.05

-0.285 (-1.64%)

  • 22

    Oct

  • 29

    Oct

  • 30

    Oct

  • 04

    Nov

  • 13

    Nov

  • 19

    Nov

  • 20

    Nov

PCAR Paccar
$66.68

0.4 (0.60%)

07/02/19
LOOP
07/02/19
DOWNGRADE
Target $62
LOOP
Sell
Paccar downgraded to Sell at Loop Capital on lower economic outlook
Loop Capital analyst downgraded Paccar to to Sell from Hold and lowered his price target on the shares to $62 from $70. In a research note to investors, Kaufman says that despite more positive headlines on trade this past weekend, he continues to see a broader-based deterioration in the level of activity across key global economies and the U.S. economy, leading to continued high inventories across multiple industries. The net impact of this has bee broadening out in levels of weaker demand for both rail and truck traffic, the result of slower industrial production, and creates a more problematic outlook.
07/24/19
JPMS
07/24/19
UPGRADE
Target $67
JPMS
Neutral
Paccar upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Ann Duigan upgraded Paccar to Neutral from Underweight and raised her price target for the shares to $67 from $66. The analyst cites valuation for the upgrade following the recent selloff in the shares.
07/02/19
JPMS
07/02/19
NO CHANGE
JPMS
June Class 8 truck orders drop 69% year-over-year, says JPMorgan
According to ACT Research, Class 8 net orders in June were 13,000 units, down 69% year-over-year, JPMorgan analyst Ann Duignan tells investors in a research note. The analyst points out that truck orders have the largest incremental impact on Navistar (NAV), Paccar (PCAR), Cummins (CMI), Eaton (ETN), Wabco (WBC) and Allison Transmission (ALSN).
08/28/19
CLVD
08/28/19
NO CHANGE
CLVD
Truck survey flags production cuts, deteriorating used truck fundamentals, says Cleveland Research
Cleveland Research analyst Adam Uhlman says his North American truck dealer survey has flagged deteriorating used truck fundamentals recently, as well as fleets deferring second half of 2019 deliveries into 2020. Supplier sources indicate Navistar (NAV) and Paccar (PCAR) plan to cut build rates over the next two months, he adds. The analyst believes additional cuts unfold in Q4 and build rates deteriorate further through 2020 unless order rates recover significantly above the normal seasonal increase in Q4. Meanwhile, Uhlman says new news this quarter is used truck pricing has begun to deteriorate more meaningfully which has caused concern for 2020 activity. Consensus estimates for Paccar and Cummins (CMI) appear too high to him going into 2020, even though expectations for the group have been quite low for some time. The analyst continues to see downside risk to the group in the medium-term. Uhlman has Neutral rating on all three stocks.
NAV Navistar
$26.83

0.29 (1.09%)

09/06/19
09/06/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Kellogg (K) upgraded to Buy from Neutral at Goldman Sachs with analyst Jason English saying the stock is the "most compelling value left in snacks" and has a visible path to accelerating its organic sales growth and growing its margins. 2. DocuSign (DOCU) upgraded to Outperform from Neutral at Wedbush with analyst Daniel Ives saying the company returned to its "usual beat and raise story," proving last quarter was a "small blip on the radar." 3. Agco (AGCO) upgraded to Buy from Hold at Stifel with analyst Stanley Elliott saying after raveling with management, the analyst is "more encouraged" with the company's margin and market share initiatives. 4. Navistar (NAV) upgraded to Neutral from Sell at Goldman Sachs with analyst Jerry Revich saying he has a positive view of management's "newly cautious" view on 2020 truck demand and he believes freight rates appear to have stabilized. 5. Cheesecake Factory (CAKE) upgraded to Outperform from Market Perform at Wells Fargo with analyst Jon Tower saying the recently announced acquisition of Fox Restaurant Concepts not only transforms the company's growth profile, but also diversifies its real estate footprint and leverages its existing infrastructure, human capital and purchasing scale. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/06/19
GSCO
09/06/19
UPGRADE
Target $26
GSCO
Neutral
Goldman Sachs upgrades Navistar to Neutral on balanced risk/reward
Goldman Sachs analyst Jerry Revich upgraded Navistar International to Neutral from Sell with an unchanged price target of $26. The analyst has a positive view of management's "newly cautious" view on 2020 truck demand and he believes freight rates appear to have stabilized. With the stock trading near his price target, Revich sees a balanced risk/reward on the length on the length of the truck cycle and Navistar's margin performance outlook.
09/06/19
GSCO
09/06/19
UPGRADE
Target $26
GSCO
Neutral
Navistar upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Jerry Revich upgraded Navistar International to Neutral from Sell with a price target of $26.
09/23/19
BARD
09/23/19
NO CHANGE
Target $38
BARD
Outperform
Navistar has most potential upside in trucking space, says Baird
Baird analyst David Leiker attended the Navistar analyst Day which offered better visibility into its upside opportunity and said it has the best upside in the trucking space. He said it remains a top idea and believes the story remains compelling, Leiker reiterated his Outperform rating and $38 price target on Navistar shares.
OSK Oshkosh
$71.43

-1.76 (-2.40%)

09/11/19
JPMS
09/11/19
UPGRADE
Target $90
JPMS
Overweight
Oshkosh upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Ann Duignan upgraded Oshkosh to Overweight from Neutral and raised her price target for the shares to $90 from $85. The shares look undervalued with "relatively limited" downside risk to earnings estimates, Duignan tells investors in a research note.
09/11/19
09/11/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Micron (MU) upgraded to Buy from Neutral at Longbow with analyst Nikolay Todorov saying his channel checks indicate upside in shipments and improving DRAM and NAND pricing fundamentals. 2. Alliance Data (ADS) upgraded to Buy from Neutral at Goldman Sachs with analyst Ryan Nash saying after peaking at $310 in 2015, shares of Alliance Data are off 57% as the company has "battled a long list of issues," including credit normalization, lower recoveries and retailer struggles leading to slower growth. 3. Alcoa (AA) upgraded to Outperform from Neutral at Credit Suisse with analyst Curt Woodworth saying he expects alumina prices to recover on "significant" capacity cuts in China, an end to inventory destocking, and the Alpart shutdown. 4. Callaway Golf (ELY) upgraded to Outperform from Market Perform at Raymond James with analyst Joseph Altobello citing the firm's sum-of-the-parts base case valuation on Callaway's golf club, ball, apparel and gear business, the Jack Wolfskin business and Callaway's TopGolf investment. 5. Oshkosh (OSK) and Agco (AGCO) upgraded to Overweight from Neutral at JPMorgan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/11/19
JPMS
09/11/19
NO CHANGE
JPMS
In Machinery shift, JPMorgan upgrades Agco and Oshkosh, cuts Actuant
With her U.S. Machinery coverage universe underperforming the broader market year-to-date, but outperforming since Labor Day amid a rotation into cyclicals, JPMorgan analyst Ann Duignan established December 2020 price targets based on where she believes we are in the cycle for end market demand. The analyst sees North America and Europe truck demand at or beyond peak, North America construction equipment "perhaps rolling over" in 2020, North America agriculture equipment demand "likely stagnating" near mid-cycle, and mining equipment "slowly approaching" mid-cycle. Within this framework, Duignan this morning upgraded both Agco (AGCO) and Oshkosh (OSK) to Overweight from Neutral, saying both stocks look undervalued with relatively limited downside risk to earnings estimates. Additionally, the analyst downgraded Actuant (ATU) to Underweight from Neutral, saying the risks appear weighted to the downside at current valuation levels. She sees elevated risk of management overpaying for acquisitions should it pursue the pipeline of potential targets. Duignan also maintained Overweight ratings on Eaton (ETN), Caterpillar (CAT) and Terex (TEX), and Underweight ratings on Deere (DE) and Allison Transmission (ALSN).
08/28/19
DOTC
08/28/19
INITIATION
Target $80
DOTC
Buy
Oshkosh initiated with a Buy at Dougherty
Dougherty analyst Michael Shlisky initiated Oshkosh with a Buy and $80 price target saying its well positioned to outperform the broader Machinery sector given its exposure to governmental business. Additionally, Shlisky thinks recent restructuring efforts and focus on operational excellence positions Oshkosh better than peers ahead of a potential downturn.
CMI Cummins
$154.02

-0.06 (-0.04%)

07/31/19
FBCO
07/31/19
NO CHANGE
Target $203
FBCO
Outperform
Cummins price target raised to $203 from $198 at Credit Suisse
Credit Suisse analyst Jamie Cook raised his price target for Cummins to $203 from $198 saying that even with lower sales, margins are "resilient" and the forecast unchanged. Further, the analyst believes the company is proactively getting ahead of the pending downturn and is well prepared to streamline costs and manage for solid decrementals.He reiterates an Outperform rating on the shares.
07/16/19
STPT
07/16/19
DOWNGRADE
STPT
Hold
Cummins downgraded to Hold from Buy at Standpoint Research
Standpoint Research analyst Ronnie Moas downgraded Cummins to Hold from Buy, noting that he believes fair value for the stock is in the $180-$190 range.
WNC Wabash
$13.50

-0.05 (-0.37%)

07/31/19
CHLM
07/31/19
DOWNGRADE
CHLM
Hold
Wabash downgraded to Hold from Buy at Craig-Hallum
08/01/19
08/01/19
DOWNGRADE
Target $18

Hold
Wabash downgraded to Hold at Craig-Hallum
As previously reported, Craig-Hallum analyst Steve Dyer downgraded Wabash to Hold from Buy, with a $18 price target. While the analyst acknowledges the company's "strong" results, he believes the industry is becoming more challenging.
07/19/19
07/19/19
DOWNGRADE

Negative
Update: Wabash downgraded to Negative following checks at OTR Global
As previously reported, OTR Global downgraded Wabash to Negative from Mixed. The firm's checks indicate trailer dealer expectations for 2019 heavy-duty trailer sales have deteriorated significantly since April due to weak demand, increased cancellations, and softer freight rates.
07/19/19
OTRG
07/19/19
DOWNGRADE
OTRG
Negative
Wabash downgraded to Negative from Mixed at OTR Global
MTOR Meritor
$17.05

-0.285 (-1.64%)

05/21/19
RBCM
05/21/19
NO CHANGE
Target $25
RBCM
Sector Perform
Meritor management discussions increase confidence in M2022, says RBC Capital
RBC Capital analyst Joseph Spak kept his Sector Perform rating and $25 price target on Meritor but noted that his recent meetings with its CEO and CFO were "constructive" as they boosted his confidence in the company's ability to achieve its medium-term targets outlined by the M2022 strategy plans. The analyst states that the discussion implied a normalization view for the company's North America Class 8 trucking toward a volume level of about 250K units. Spak also contends that the recent sell-off in in Meritor stock price may offer a "nice tactical entry point" based on the management's latest outlook.
05/06/19
LBOW
05/06/19
DOWNGRADE
LBOW
Neutral
Meritor downgraded to Neutral from Buy at Longbow
04/24/19
LBOW
04/24/19
NO CHANGE
Target $28
LBOW
Buy
Meritor price target raised to $28 from $25 at Longbow
Longbow analyst Faheem Sabeiha raised his estimates for Meritor to reflect a higher North America Class 8 production forecast of 347,000 units, up from his prior view of 335,000 units. The analyst, who expects Meritor to deliver adjusted EPS above current consensus estimates when it reports on May 1, raised his price target on the stock to $28 and keeps a Buy rating on the shares.
03/25/19
PIPR
03/25/19
NO CHANGE
Target $36
PIPR
Overweight
Investors should continue to own Meritor, says Piper Jaffray
After hosting investor meetings with management, Piper Jaffray analyst Alexander Potter continues to rank Meritor among his top picks, "both in 2019 and beyond." Cyclical or macro "noise" may cause dislocation in the coming year, but the stock should be bought on any pullback, Potter tells investors in a research note partially titled "We Still Think Investors Should be Owning MTOR." The analyst believes Meritor has an attractive position in the electric vehicle sector and reiterates an Overweight rating on the shares with a $36 price target.

TODAY'S FREE FLY STORIES

STOK

Stoke Therapeutics

$28.91

3.99 (16.01%)

10:04
12/08/19
12/08
10:04
12/08/19
10:04
Hot Stocks
Stoke Therapeutics presents STK-001 preclinical data in Dravet syndrome »

Stoke Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

09:25
12/08/19
12/08
09:25
12/08/19
09:25
Hot Stocks
Autolus announces new data highlighting progress on AUTO3 »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

AGIO

Agios Pharmaceuticals

$40.93

0.81 (2.02%)

09:22
12/08/19
12/08
09:22
12/08/19
09:22
Hot Stocks
Agios says proof-of-concept has been established for mitapivat »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

ZIOP

Ziopharm

$5.16

0.06 (1.18%)

09:20
12/08/19
12/08
09:20
12/08/19
09:20
Hot Stocks
Ziopharm reports pre-clinical data of Rapid Personalized Manufacture »

Ziopharm Oncology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

TGTX

TG Therapeutics

$7.11

-0.57 (-7.42%)

09:18
12/08/19
12/08
09:18
12/08/19
09:18
Hot Stocks
TG Therapeutics reports triple therapy data from Phase I/II study of ublitux »

TG Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

KPTI

Karyopharm

$16.30

-1.15 (-6.59%)

09:16
12/08/19
12/08
09:16
12/08/19
09:16
Hot Stocks
Karyopharm says four posters will be presented at ASH »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPHA

Innate Pharma

$6.30

(0.00%)

09:13
12/08/19
12/08
09:13
12/08/19
09:13
Hot Stocks
Innate Pharma reports long-term data from Phase III trial of Lumoxiti »

Innate Pharma shared new,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REGN

Regeneron

$372.26

4.02 (1.09%)

09:11
12/08/19
12/08
09:11
12/08/19
09:11
Hot Stocks
Regeneron reports initial data for REGN5458 in myeloma patients »

Regeneron Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

09:09
12/08/19
12/08
09:09
12/08/19
09:09
Hot Stocks
Blueprint reports 77% overall response rate in 48 patients from Explorer trial »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

BPMC

Blueprint Medicines

$78.50

3.92 (5.26%)

09:06
12/08/19
12/08
09:06
12/08/19
09:06
Hot Stocks
Blueprint announces initial data from Phase 2 Pioneer trial in mastocytosis »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

PCG

PG&E

$9.65

-0.13 (-1.33%)

08:12
12/08/19
12/08
08:12
12/08/19
08:12
Periodicals
PG&E settlement threatens bondholders plan, WSJ reports »

PG&E's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

SYRS

Syros Pharmaceuticals

$4.60

-0.02 (-0.43%)

08:08
12/08/19
12/08
08:08
12/08/19
08:08
Hot Stocks
Syros announces fetal hemoglobin repressor using gene control platform »

Syros Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

08:06
12/08/19
12/08
08:06
12/08/19
08:06
Hot Stocks
AbbVie says post-hoc analysis supports benefit of venetoclax in combination »

AbbVie presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

08:03
12/08/19
12/08
08:03
12/08/19
08:03
Hot Stocks
Genentech reports data from two Phase III Venclexta studies in leukemia »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 16

    Dec

ORTX

Orchard Therapeutics

$11.85

0.37 (3.22%)

07:59
12/08/19
12/08
07:59
12/08/19
07:59
Hot Stocks
Orchard to present data from multiple programs at ASH meeting »

Orchard Therapeutics said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

06:55
12/08/19
12/08
06:55
12/08/19
06:55
Conference/Events
Sierra Oncology to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

RUHN

Ruhnn

$6.19

-0.2 (-3.13%)

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Ruhnn management to meet with Mizuho »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Dec

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Sierra Oncology to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

04:55
12/08/19
12/08
04:55
12/08/19
04:55
Conference/Events
Piper Jaffray biotech analysts to hold a KOL luncheon »

Biotech Analysts hold a…

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

19:31
12/07/19
12/07
19:31
12/07/19
19:31
Hot Stocks
Magenta reports results from MGTA-145 stem cell mobilization program »

Magenta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

PFE

Pfizer

$38.29

0.26 (0.68%)

, BMY

Bristol-Myers

$59.94

0.435 (0.73%)

19:29
12/07/19
12/07
19:29
12/07/19
19:29
Hot Stocks
Bristol-Myers Squibb-Pfizer Alliance reports analysis of Eliquis »

The Bristol-Myers…

PFE

Pfizer

$38.29

0.26 (0.68%)

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

UMRX

Unum Therapeutics

$0.70

0.0177 (2.61%)

19:25
12/07/19
12/07
19:25
12/07/19
19:25
Hot Stocks
Unum Therapeutics announces Phase 1 clinical updates for T-cell therapies »

Unum Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

MGTA

Magenta Therapeutics

$13.29

0.3 (2.31%)

19:25
12/07/19
12/07
19:25
12/07/19
19:25
Conference/Events
Magenta Therapeutics to hold an investor and analyst event »

Investor and Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

AUTL

Autolus Therapeutics

$14.60

-0.18 (-1.22%)

19:23
12/07/19
12/07
19:23
12/07/19
19:23
Hot Stocks
Autolus presents new data on T cell therapies in leukemia, lymphoma »

Autolus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 09

    Dec

BMY

Bristol-Myers

$59.94

0.435 (0.73%)

19:19
12/07/19
12/07
19:19
12/07/19
19:19
Hot Stocks
Bristol-Myers says lisocabtagene maraleucel study met both endpoints »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 09

    Dec

  • 11

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.